Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

Research output: Contribution to journalArticle

Abstract

Dasatinib (DAS) and interferon-α have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-α2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 μg/week and it increased to 25 μg/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major molecular response was achieved in 10%, 57%, 84% and 89% of patients at M3, M6, M12 and M18, respectively. At M12, MR 4 was achieved by 46% and MR 4.5 by 27% of patients. No patients progressed to advanced phase. In conclusion, the combination treatment appeared safe with very promising efficacy. A randomized comparison of DAS±PegIFN is warranted.

Details

Authors
  • H. Hjorth-Hansen
  • J. Stentoft
  • J. Richter
  • P. Koskenvesa
  • M. Höglund
  • A. Dreimane
  • K. Porkka
  • T. Gedde-Dahl
  • B. T. Gjertsen
  • F. X. Gruber
  • L. Stenke
  • K. M. Eriksson
  • B. Markevärn
  • A. Lübking
  • H. Vestergaard
  • L. Udby
  • O. W. Bjerrum
  • I. Persson
  • S. Mustjoki
  • U. Olsson-Strömberg
External organisations
  • Norwegian University of Science and Technology
  • Aarhus University Hospital
  • Skåne University Hospital
  • University of Helsinki
  • Uppsala University Hospital
  • Linköping University
  • Norwegian Radium Hospital
  • Haukeland University Hospital
  • University Hospital of North Norway
  • Karolinska University Hospital
  • Sunderby Hospital
  • Norrland University Hospital
  • Odense University Hospital
  • Zealand University Hospital
  • Copenhagen University Hospital
  • Uppsala University
  • St. Olav’s University Hospital
  • Östergötland County Council
  • University of Bergen
  • Karolinska Institutet
  • Helsinki University Central Hospital
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Hematology
  • Cancer and Oncology
Original languageEnglish
Pages (from-to)1853-1860
Number of pages8
JournalLeukemia
Volume30
Issue number9
Publication statusPublished - 2016 Sep 1
Publication categoryResearch
Peer-reviewedYes
Externally publishedYes